Halozyme Therapeutics, Inc. (HALO) is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on HALO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Halozyme Therapeutics could be a solid choice for investors.
Current Quarter Estimates for HALO
Current Year Estimates for HALO
Meanwhile, Halozyme Therapeutics’ current year figures are also looking quite promising. The consensus estimate trend has seen a boost for this time frame, narrowing from a loss of 49 cents per share 30 days ago to a loss of 40 cents per share today, an increase of 18.4%.